EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase 2b

Ensembl ID : ENSOKIG00005038237
Gene Symbol: MAP2K2B
1 Cross references
194 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSOKIG00005048272
Gene Symbol: MAP3K1
1 Cross references
154 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSOKIG00005049180
Gene Symbol: MAP3K1
3 Cross references
155 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSOKIG00005048350
Gene Symbol: MAP3K10
3 Cross references
176 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSOKIG00005009084
Gene Symbol: MAP3K10
1 Cross references
176 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSOKIG00005010962
Gene Symbol: MAP3K11
1 Cross references
176 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSOKIG00005029344
Gene Symbol: MAP3K11
3 Cross references
176 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSOKIG00005022361
Gene Symbol: MAP3K12
1 Cross references
179 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSOKIG00005029888
Gene Symbol: MAP3K12
3 Cross references
179 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSOKIG00005020315
Gene Symbol: LOC109906971
3 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSOKIG00005006865
Gene Symbol: MAP3K12
1 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSOKIG00005046146
Gene Symbol: MAP3K13
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).